Human Platelets Take up Anti-VEGF Agents

Figure 6

Immunogold staining using immunoelectron microscopy in human platelets exposed to pharmacologic inhibitors: staurosporine and cytochalasin D. Gold particle (1 nm)-labeled anti-VEGF agents: (a) ranibizumab, (b) aflibercept, and (c) bevacizumab. (a–c) Platelets without exposure to pharmacologic inhibitors. (d–f) Platelets exposed to staurosporine. (g–i) Platelets exposed to cytochalasin D. Scale bar represents 1 µm.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)